Mr. Weiler to Share Insights with the Region's Most Promising Early Stage Companies

WALTHAM, Mass.--(BUSINESS WIRE)--

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that President and CEO Bob Weiler will participate in the MassTLC Innovation 2008 unConference, Thursday, October 2 at Sun Microsystems' Burlington, Mass. campus.

Designed to foster local entrepreneurship and drive innovation, the unConference brings together four generations of the region's most successful business leaders and investors to provide focused, timely help to early stage companies. Mr. Weiler will offer advice on how to build and manage a board of directors.

Instead of planned sessions and passive audiences, the unConference agenda is set by the attendees, where 8-12 discussions run in parallel in each of the four sessions and where everyone gets to know each other by gathering around areas of common interest. For more information visit: http://www.masstlc.org/eve/innovation.aspx.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm(TM)), phase I clinic automation (LabPas(TM)), clinical data management (Clintrial(TM)), clinical trials signal detection (CTSD(TM)), strategic pharmacovigilance (Empirica Signal(TM)) and Signal Management, adverse event reporting (Empirica Trace(TM)), applied data standards (WebSDM(TM)) and Web-integrated interactive response technologies (Clarix(TM)). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 280 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Source: Phase Forward